← boardnext 2027-09next 2028-03-01next 2030-12
IOVA
Iovance Biotherapeutics, Inc.distress 4/10 · elevated risk$5.07-2%today-7% from 52w high
Oncology 3
Lead: Metastatic Melanoma · target PD-1 · est. market ~$10B (approx, global)
Revenue
$71M
Liquidity
$313M
Runway
1.2 yrs
Shares 1y
+23%
Price & events
+88.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
+8.8%
1W
+14.2%
1M
+45.7%
3M
+92.0%
6M
+27.7%
1Y
-41.7%
2Y
-78.0%
5Y
-89.0%
All
Overview
- Market Cap
- $2.26B
- Volume
- 1.52M
- 52 Week Range
- $1.81 – $5.48
- Total Shares
- 446.50M
- Float Shares
- 387.93M
- Short %
- 24.10%
- % Held by Insiders
- 0.34%
- % Held by Institutions
- 67.72%
- RVOL
- 0.10x
- Beta
- 0.69
Pipeline stages · 3 programs
IOV-3001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Lifileucel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LN-145
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 9 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 1/2 | IOV-4001 | Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | — | recruiting |
| 2028-03-01 Estimated 50% readout ~2028-05-15 | Phase 3 | Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Periodfast trackbreakthroughrmat | Metastatic Melanoma, Unresectable Melanoma, Melanoma | — | recruiting |
| 2028-05 Estimated 50% readout ~2028-06-15 | Phase 2 | Lifileucelfast trackbreakthroughrmat | Endometrial Cancer | — | recruiting |
| 2030-12 Estimated 50% readout ~2031-01-15 | Phase 2 | LN-145 | Metastatic Non Small Cell Lung Cancer | — | recruiting |
| 2032-06 Estimated 50% readout ~2032-07-16 | Phase 1/2 | IOV-3001 | Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma | — | recruiting |
Show all 9 trials · 4 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2032-12 Estimated 50% readout ~2033-01-15 | Phase 2 | Lifileucelfast trackbreakthroughrmat | Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma | — | active not recruiting |
| 2026-07 | Phase 1 | LN-145/LN-144 | Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma, Ewing Sarcoma | 40 | active not recruiting |
| 2026-02-20 | Phase 2 | Lifileucel, LN-145, Pembrolizumabfast trackbreakthroughrmat | Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer | 225 | terminated |
| 2025-08-22 | Phase 2 | LN-145, pembrolizumab | Cervical Carcinoma | 210 | terminated |
Catalyst news & presentations · 9
- 2H 2027Guided 55%regulatory submissionFiled (NDA/BLA)lifileucel · Potential FDA approval and launch for lifileucel in NSCLCSEC 8-K
- 1H 2027Guided 55%regulatory submissionFiled (NDA/BLA)lifileucel · Potential regulatory approval decisions in Canada, EU, Australia, SwitzerlandSEC 8-K
- 2026Guided 40%readoutPhase 2Lifileucel · Completion of enrollment and data update for IOV-LUN-202 trial expected in 2026.SEC 8-K
- 2026Guided 40%enrollment completesecondaryPhase 2lifileucel · Complete enrollment in IOV-LUN-202 registrational trialSEC 8-K
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)lifileucel · Resubmit MAA to EMA for AmtagviSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026trial initiationsecondarylifileucel · Commence single arm registrational trial in UPS and DDLPSSEC 8-K
- 2025regulatory submissionFiled (NDA/BLA)IOV-5001 · Planned IND submission for IL-12 tethered TILSEC 8-K
- 3Q 2024regulatory submissionFiled (NDA/BLA)IOV-3001 · Planned IND submission for IL-2 analogSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $9 (+74% upside) · 10 analysts
- 2026-05-08Chardan CapitalBuy
- 2026-04-10Chardan CapitalBuy
- 2026-03-05UBSNeutral
- 2026-03-03CitizensMarket Perform → Market Outperform
- 2026-02-25BarclaysOverweight
- 2026-02-25CitizensMarket Perform → Market Outperform
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- TNGXTango Therapeutics, Inc.$4.0B · D5
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-22Iovance Biotherapeutics stock hits 52-week high at $5.64 By Investing.com - Investing.com Nigeria
- 2026-07-22REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
- 2026-07-21Correction: Head and Neck Squamous Cell Carcinoma Market is - GlobeNewswire
- 2026-07-18Iovance Biotherapeutics (NASDAQ:IOVA) shares jump 18% as Amtagvi sales test approaches - TechStock²
- 2026-07-17Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
- 2026-07-17Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
- 2026-07-17Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
- 2026-07-17Iovance Gives 17 New Employees Options That Vest Over 3 Years - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.